The Ingenio, Advantio pacemakers feature RightRate pacing technology which is designed to treat chronotropic incompetence (CI).

RightRate technology includes Boston Scientific’s minute ventilation (MV) sensor which adds programming options to promote ease of use and in-clinic time savings.

The company said the Ingenio family of pacemakers and CRT-Ps are expected to be compatible with its new Latitude NXT remote patient management system, which enables physicians to conduct remote follow-ups of these device patients to monitor specific pacemaker information and heart health status.

The system is designed to detect clinical events between scheduled visits and send relevant data directly to a secure physician-accessible website via landline or cellular-based telephone technology.

The Ingenio and Advantio pacemakers are currently under review by the US Food and Drug Administration and not available for sale in the US.